| abstract |
REFERS TO BICYCLE PYRIMIDINONE COMPOUNDS OF FORMULA (I) WHERE R1 IS (Ar1) ALKYL, (Ar1) (WITH (R8) (R9) ALKYL, (Ar1) (CO2R14) ALKYL, AMONG OTHERS; R2 IS H, RENT, AMONG OTHERS; Ar1 IS (a), (b), WHERE R3 IS H, HALO, WITH (R8) (R9), SO2R7, Ar2, AMONG OTHERS; Ar2 IS TETRAZOLYL, TRIAZOLYL, OXADIAZOLYL, AMONG OTHERS, OPTIONALLY SUBSTITUTE; XYT IS C (R14) 2C (R14) 2OC (CR14) 2, C (R14) 2C (R14) 2OC (CR14) 2C (CR14) 2, AMONG OTHERS; R14 IS H, ALKYL, OR TWO R14 TAKEN TOGETHER FORM CH2 (CH2 ) 2-5, CH2CH2OCH2CH2, AMONG OTHERS PREFERRED: N - ((4-FLUOROPHENYL) METHYL) -3-HYDROXY-10,10-DIMETHYL-4-OXO-6,7,9,10-TETRAHYDRO-4H- PYRIMIDO [1,2-d] [1,4] OXAZEPIN-2-CARBOXAMIDE, N - ((4-FLUORO-2- (1H-1,2,4-TRIAZOL-1-IL) PHENYL) METHYL) -3 -HYDROXY-10,10-DIMETHYL-4-OXO-6,7,9,10-TETRAHYDRO-4H-PYRIMIDO [1,2-d] [1,4] OXAZEPIN-2-CARBOXAMIDE, AMONG OTHERS. ALSO REFERRED TO TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE THESE COMPOUNDS ARE INHIBITORS OF HIV INTEGRASE AND ARE USEFUL FOR THE TREATMENT OF PATIENTS INFECTED BY HIV OR AIDS |